Plasma Fractionation Market Outlook With A Closer Look At Growth Drivers And Industry Shifts

 The Business Research Company’s 2026 market reports incorporate enhanced features, including market attractiveness scoring and analysis, total addressable market evaluation, a company scoring matrix, an interactive Excel data dashboard, refined supply chain analysis, insights on emerging startups, and overviews of key products, all aimed at improving the depth, usability, and strategic relevance of the insights delivered.

 
 What Is The Expected Market Size Of The Plasma Fractionation Market Across The Forecast Years?
 The plasma fractionation market size has grown rapidly in recent years. It will grow from $34.14 billion in 2025 to $37.63 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to growth in demand for immunoglobulins, increased prevalence of hematological disorders, technological advancements in plasma fractionation, expansion of hospital and clinical infrastructure, rise in awareness about plasma-derived therapies.
 
 The plasma fractionation market size is expected to see rapid growth in the next few years. It will grow to $55.85 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing adoption of precision medicine, integration of ai in plasma manufacturing, expansion of global biopharmaceutical collaborations, rising investments in plasma collection centers, development of novel plasma-derived therapies. Major trends in the forecast period include advanced plasma fractionation techniques, biopharmaceutical product diversification, enhanced quality control and regulatory compliance, expansion of contract manufacturing organizations (cmos/cdmos), supply chain optimization in plasma products.
 
 Download Your Free Report Sample:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=7543&type=smp
 
 Which Drivers Are Accelerating Growth In The Plasma Fractionation Market? 
 The increasing number of chronic diseases is expected to propel the growth of the plasma fractionation market going forward. Chronic diseases are defined as conditions that last 1 year or more and require ongoing medical attention, their examples include diseases such as heart disease, cancer, and diabetes. Treatment of patients with chronic diseases through access to plasma products reduces morbidity, improves the quality of life, and is cost-effective, this will in turn increase the demand for plasma fractionation. For instance, in March 2025, according to GOV.UK, a UK-based non-profit government organization, GP recorded type 2 diabetes prevalence in adults as 7.0% for those aged 17 and over in England in March 2024, which was an increase from 6.8% in March 2023. Therefore, an increasing number of chronic diseases of all ages is expected to propel the plasma fractionation market growth.
 
 Who Are The Major Players In The Plasma Fractionation Market?
 The plasma fractionation market covered in this report is segmented — 
 
 1) By Product: Immunoglobulins, Coagulation Factors, Albumin, Protease Inhibitors 
 2) By Application: Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology
 3) By End User: Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes
 
 Subsegments:
 1) By Immunoglobulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG) 
 2) By Coagulation Factors: Factor VIII, Factor IX, Prothrombin Complex Concentrates (PCC) 
 3) By Albumin: Human Albumin, Bovine Serum Albumin (BSA) 
 4) By Protease Inhibitors: Alpha-1 Antitrypsin (AAT), C1 Esterase Inhibitor (C1-INH) 
 
 What Are The Most Important Trends In The Plasma Fractionation Market?
 Major companies operating in the market are introducing new technologies like hi-tech facility processes that turn donated human plasma into important medicines and use advanced technology to make the process more efficient and safer. For instance, in March 2023, CSL Behring, a German-based company, opened a new $470 million plasma fractionation facility that uses cutting-edge technology to improve the efficiency and safety of plasma processing, ensuring higher quality and more reliable medicines. By increasing the supply of these critical medicines, the facility helps meet the growing demand, ensuring more patients have access to life-saving treatments. With the advanced automation and self-cleaning systems, it reduces the risk of contamination and improves overall hygienic conditions, enhancing patient safety.
 
 How Is The Plasma Fractionation Market Divided Into Segment Categories?
 The plasma fractionation market covered in this report is segmented — 
 
 1) By Product: Immunoglobulins, Coagulation Factors, Albumin, Protease Inhibitors 
 2) By Application: Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology
 3) By End User: Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes
 
 Subsegments:
 1) By Immunoglobulins: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG) 
 2) By Coagulation Factors: Factor VIII, Factor IX, Prothrombin Complex Concentrates (PCC) 
 3) By Albumin: Human Albumin, Bovine Serum Albumin (BSA) 
 4) By Protease Inhibitors: Alpha-1 Antitrypsin (AAT), C1 Esterase Inhibitor (C1-INH) 
 
 Explore the Complete Plasma Fractionation Market Report:
 https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report
 
 Which Regions Are Anticipated To Witness The Fastest Growth In The Plasma Fractionation Market?
 https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report
 
 #Contact Us:#
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: marketing@tbrc.info
 
 #Follow Us On:#
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company